SCHEMBL2397421

SCHEMBL2397421

CC12CCCc3cc(NC(=O)c4ccc(C(=O)O)s4)cc(c31)CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.45
RAB9A P51151 7/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
NFKB1 P19838 4/20 0.45
NFKB2 Q00653 4/20 0.45
RELA Q04206 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
POLB P06746 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
MAPT P10636 6/20 0.40
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.38
TP53 P04637 3/20 0.38
RXFP1 Q9HBX9 2/20 0.38
RXRA P19793 2/20 0.38
RXRB P28702 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396265 0.91 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL11955422 0.81 MEN1 (0.55) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2396267 0.81 RNASEH1 (0.38) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2394784 0.78 NPC1 (0.47) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2394731 0.77 KDM4E (0.48) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2396649 0.75 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL2394957 0.75 MEN1 (0.54) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL11956667 0.74 P4HTM (0.53) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL2395484 0.72 AR (0.41) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL829589 0.72 RXRA (0.43) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG NPC1 905/4885RAB9A 1612/4885SMN1; SMN2 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.